A strategy for increasing the efficiency of psychopharmacological treatment of hyperkinetic behavior disorder with pantogam

Kupriyanova, T. A.; Koren, Ela; Alabusheva, N N

doi:10.17116/jnevro201711711275-79

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reboxetine is a specific NRI [33] suggested as potentially useful for attention and executive functions [34]. Reboxetine was tested in adults [35] and children [36] with suggestions of partial efficacy and with adverse effects including headache, low appetite, sleep disturbances, anxiety and irritability.…”

Section: Nris On Holdmentioning

confidence: 99%

See 1 more Smart Citation

Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)

Pozzi

Bertella

Gatti

et al. 2020

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Introduction: Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder affecting up to 5.3% of children and 2.5% of adults depending on the country considered. Current pharmacological treatments for ADHD are based on stimulant or non-stimulant medications, targeting dopaminergic and noradrenergic systems in the frontal cortex and dopaminergic system in the basal ganglia. These drugs are effective and safe for the majority of patients, whereas about 20% of treated patients do not tolerate current therapies or experience insufficient efficacy. The adequate treatment of ADHD is necessary to allow a proper social placement and prevent the acquisition of additional, more severe, comorbidities. Areas covered: We conducted a review of the scientific literature and of unpublished/ongoing clinical trials to summarize the advances made in the last 10 years (2010-2020) for the pharmacological treatment of ADHD. We found many pharmacological mechanisms beyond dopaminergic and noradrenergic ones have been investigated in patients. Expert opinion: Some emerging drugs for ADHD may be promising as add-on treatment especially in children, amantadine to enhance cognitive functions and tipepidine for hyperactivity/impulsivity. Stand-alone emerging treatments for ADHD include viloxazine and dasotraline, which will soon have more clinical data available to support market access requests.

show abstract

Section: Nris On Holdmentioning

confidence: 99%

“…There were no serious adverse events and NPG performed similarly to placebo regarding safety. NPG was tested also as add-on [34] at the maximum dose of 1250 mg/d, in a single-arm study lasting 2 months. The additional NPG was efficacious from the second week, on the CHIP subscales school performance and risk aversion.…”

Section: Gabaergic Transmissionmentioning

confidence: 99%

Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)

Pozzi

Bertella

Gatti

et al. 2020

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

show abstract

Hopantomide in pediatric neurological practice: outlooks

Пылаева¹

2021

Rus. ž. det. nevrol.

View full text Add to dashboard Cite

Hopantomide® is a drug containing calcium salt of hopantenic acid. The drug is registered and produced in Russia (Usolye-Siberian Chemical Pharmaceutical Factory) with the use of own raw materials and goes through a full production cycle, which guarantees quality control at every stage. Hopantomide belongs to nootropics and has neurometabolic, neuroprotective, and neurotrophic properties, as well as anticonvulsant action. According to the package insert and results of the studies evaluating the efficacy of hopantenic acid, Hopantomide has a number of positive therapeutic effects. It increases brain resistance to hypoxia and toxic substances, stimulates anabolic processes in neurons, improves mental and physical performance, combines moderate sedative action with mild stimulating effect, reduces motor excitability with simultaneous regulation of behavior, improves the metabolism of gamma-aminobutyric acid and normalizes its level in individuals with chronic alcohol intoxication and after alcohol withdrawal, has anxiolytic and thymoleptic properties, inhibits the abnormal bladder reflex and detrusor tone. This ensures high efficacy of Hopantomide in the treatment of various nervous diseases in different age groups. In our opinion, the combination of various positive effects of just one drug can significantly reduce the pharmacological burden. In this review, we discuss well-known and potential mechanisms of action, indications for its use with a focus on Hopantomide benefits in pediatric neurological practice, and studies evaluating the efficacy of hopantenic acid in clinical practice. Particular attention is paid to the possibilities of its use in children, including those with attention deficit hyperactivity disorder and developmental delay, as well as the part of combination therapy for epilepsy together with antiepileptic drugs.Drugs containing hopantenic acid are well tolerated by patients, including children who receive it for a long time.

show abstract

A strategy for increasing the efficiency of psychopharmacological treatment of hyperkinetic behavior disorder with pantogam

Cited by 2 publications

References 16 publications

Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)

Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)

Hopantomide in pediatric neurological practice: outlooks

Contact Info

Product

Resources

About